Acrivon Therapeutics
ACRV
53 hedge funds and large institutions have $21.2M invested in Acrivon Therapeutics in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 25 closing their positions.
15.09% less ownership
Funds ownership: 71.87% → 56.78% (-15%)
16% less funds holding
Funds holding: 63 → 53 (-10)
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
40% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 25
54% less capital invested
Capital invested by funds: $45.7M → $21.2M (-$24.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$627K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$525K |
| 3 |
Jane Street
New York
|
+$428K |
| 4 |
Millennium Management
New York
|
+$407K |
| 5 |
Two Sigma Investments
New York
|
+$249K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$10.9M |
| 2 |
BlackRock
New York
|
-$729K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$369K |
| 4 |
State Street
Boston,
Massachusetts
|
-$227K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$195K |
ACRV Hedge Fund Activity: Q2 2025 in Review
53 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q2 2025, worth a combined $21.2M — down 54% from $45.7M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ACRV and 15 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 11 added.
The largest buyer was Renaissance Technologies, adding an estimated $627K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $10.9M sold.
- 53 institutional investors held Acrivon Therapeutics (ACRV) as of Q2 2025, down from 63 in Q1 2025.
- Funds reported $21.2M of Acrivon Therapeutics stock for Q2 2025, down 54% quarter-over-quarter.
- 15 funds opened new Acrivon Therapeutics positions in Q2 2025 and 25 closed out, a net change of -10 holders.
- The largest Acrivon Therapeutics buyer in Q2 2025 was Renaissance Technologies, an estimated $627K added.
- The largest Acrivon Therapeutics seller in Q2 2025 was Perceptive Advisors, an estimated $10.9M sold.
Based on aggregated 13F filings for Q2 2025.